New BioNTech (BNTX) director Nicola Blackwood files initial Form 3

Rhea-AI Filing Summary

BioNTech SE filed an initial insider ownership report for director Nicola Claire Blackwood on Form 3. The filing identifies her role as a director and, in the data provided, does not report any equity transactions or derivative positions, serving mainly as a baseline disclosure of her status as an insider.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Blackwood Nicola Claire

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Humza Bokhari, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioNTech (BNTX) Form 3 filing for Nicola Claire Blackwood show?

The Form 3 filing shows that Nicola Claire Blackwood is a director of BioNTech SE. It serves as her initial insider ownership report and, in the data provided, does not list any equity transactions or derivative positions.

Did Nicola Claire Blackwood buy or sell BioNTech (BNTX) shares in this Form 3?

No transactions are reported in this Form 3 for Nicola Claire Blackwood. The transaction summary shows zero buys, zero sells, and no derivative exercises, indicating the filing is purely an initial status disclosure.

What is the purpose of this BioNTech (BNTX) Form 3 for Nicola Claire Blackwood?

The purpose is to formally identify Nicola Claire Blackwood as an insider, specifically a director of BioNTech SE. Form 3 filings establish a baseline record from which any future Form 4 or Form 5 transactions will be tracked.

Does the BioNTech (BNTX) Form 3 mention any derivative securities for Nicola Claire Blackwood?

The derivative summary in this Form 3 is empty for Nicola Claire Blackwood. That means no options, warrants, or other derivative positions are listed in the data provided for this initial insider report.

How many transactions are summarized in Nicola Claire Blackwood’s BioNTech (BNTX) Form 3?

The transaction summary for Nicola Claire Blackwood’s Form 3 shows zero transactions. All categories, including buys, sells, gifts, tax withholding, and restructurings, are listed as zero in this initial disclosure.